Actinium Pharmaceuticals (ATNM) Sees Unusually-High Trading Volume


Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares saw unusually-strong trading volume on Monday . Approximately 6,705,500 shares changed hands during trading, an increase of 577% from the previous session’s volume of 990,819 shares.The stock last traded at $0.63 and had previously closed at $0.50.

A number of research analysts have weighed in on ATNM shares. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Thursday, April 5th. Maxim Group set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, March 28th. Finally, B. Riley set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, March 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $3.70.


Several hedge funds and other institutional investors have recently bought and sold shares of the company. Anson Funds Management LP bought a new stake in shares of Actinium Pharmaceuticals in the first quarter worth $1,502,000. Sabby Management LLC bought a new stake in shares of Actinium Pharmaceuticals in the first quarter worth $729,000. Sio Capital Management LLC bought a new stake in shares of Actinium Pharmaceuticals in the first quarter worth $393,000. Worth Venture Partners LLC bought a new stake in shares of Actinium Pharmaceuticals in the first quarter worth $140,000. Finally, D.A. Davidson & CO. increased its stake in shares of Actinium Pharmaceuticals by 227.1% in the fourth quarter. D.A. Davidson & CO. now owns 157,000 shares of the biotechnology company’s stock worth $104,000 after buying an additional 109,000 shares during the last quarter.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

Leave a Reply

Your email address will not be published.